TALS Stock Price, Talaris Therapeutics, . Quote, Chart

Market Summary

USD2.72-0.02

Delayed

-0.73%

TALS Stock Price

View Fullscreen

TALS RSI Chart

TALS Valuation

Market Cap

73.3M

Price/Earnings (Trailing)

-2.23

Price/Free Cashflow

-2.84

TALS Price/Earnings (Trailing)

TALS Profitability

Return on Equity

-9.3%

Return on Assets

-9.17%

Free Cashflow Yield

-35.23%

TALS Fundamentals

TALS Revenue

TALS Earnings

Earnings (TTM)

-32.9M

Earnings Growth (Yr)

40.83%

Earnings Growth (Qtr)

-726.11%

Breaking Down TALS Revenue

Last 7 days

5.9%

Last 30 days

1.1%

Last 90 days

-6.8%

Trailing 12 Months

16.3%

How does TALS drawdown profile look like?

TALS Financial Health

Current Ratio

62.17

TALS Investor Care

Buy Backs (1Y)

39.18%

Diluted EPS (TTM)

-4.91

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Talaris Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jul 03, 2023	fenton mary kay	sold (taxes)	-39,873	3.08	-12,946	chief financial officer
Jul 03, 2023	requadt scott	sold (taxes)	-36,300	3.08	-11,786	-
Jun 14, 2023	ildstad suzanne	sold	-32,243	2.4914	-12,942	-
Jun 13, 2023	ildstad suzanne	sold	-36,338	2.5576	-14,208	-
Jun 12, 2023	ildstad suzanne	sold	-43,725	2.5919	-16,870	-
Jun 09, 2023	ildstad suzanne	sold	-62,637	2.4642	-25,419	-
Jun 08, 2023	ildstad suzanne	sold	-100,772	2.4795	-40,642	-
Jun 07, 2023	ildstad suzanne	sold	-179,095	2.3879	-75,001	-
Jun 06, 2023	ildstad suzanne	sold	-64,595	2.5283	-25,549	-
Jun 05, 2023	ildstad suzanne	sold	-19,754	2.5194	-7,841	-

Which funds bought or sold TALS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Oct 30, 2023	FREEDOM WEALTH ALLIANCE, LLC	new	-	45,367	45,367	0.07%
Jul 22, 2022	Altium Wealth Management LLC	unchanged	-	-318,000	268,000	0.02%
May 16, 2022	Amalgamated Financial Corp.	new	-	31,000	31,000	-%

Are Funds Buying or Selling TALS?

Are funds buying TALS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TALS

No. of Funds

Unveiling Talaris Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 15, 2024	pfizer inc	4.96%	1,272,214	SC 13G/A
Feb 14, 2024	blue owl capital holdings lp	6.55%	1,332,302	SC 13G
Feb 14, 2024	hydra llc	6.6%	1,702,164	SC 13G/A
Feb 14, 2024	citadel advisors llc	0.0%	6	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	0%	0	SC 13G/A
Feb 09, 2024	tcg crossover gp i, llc	5.9%	1,477,593	SC 13G
Feb 09, 2024	blackstone holdings ii l.p.	0%	0	SC 13G/A
Feb 07, 2024	bml investment partners, l.p.	1.0%	245,500	SC 13G/A
Nov 06, 2023	hydra llc	5.9%	1,202,164	SC 13G
Oct 30, 2023	longitude capital partners iii, llc	1.6%	322,077	SC 13D/A

Recent SEC filings of Talaris Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	8-K	Current Report
May 13, 2024	10-Q	Quarterly Report
Apr 19, 2024	DEFA14A	DEFA14A
Apr 19, 2024	DEF 14A	DEF 14A
Apr 19, 2024	ARS	ARS
Mar 19, 2024	S-8	Employee Benefits Plan
Mar 19, 2024	8-K	Current Report
Mar 19, 2024	10-K	Annual Report
Mar 15, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Talaris Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Talaris Therapeutics, Inc. News

Latest updates

Talaris Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Revenue	-	538	-	-	-	-
Operating Expenses	-42.6%	9,470	16,502	24,078	-36,951	19,823
S&GA Expenses	51.2%	9,114	6,026	6,182	-12,113	4,842
R&D Expenses	-97.0%	267	8,800	13,415	-24,838	14,981
Net Income	52.4%	-7,015	-14,738	-22,497	35,665	-19,011
Free Cashflow	49.7%	-7,502	-14,919	-17,222	43,235	-13,768

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	70.8%	359	210	151	159	173	190	207	221	237	251	261	273	145	153
Current Assets	43.7%	300	209	151	156	169	8.00	198	212	228	247	258	270	143	151
Cash Equivalents	-30.0%	99.00	141	67.00	18.00	24.00	8.00	18.00	26.00	23.00	0.00	27.00	36.00	10.00	18.00
Net PPE	-11.8%	0.00	0.00	-	0.00	3.00	0.00	5.00	6.00	5.00	5.00	3.00	2.00	2.00	2.00
Liabilities	-4.2%	5.00	5.00	8.00	11.00	11.00	2.00	12.00	10.00	11.00	9.00	6.00	5.00	5.00	5.00
Current Liabilities	-3.5%	5.00	5.00	8.00	10.00	10.00	1.00	9.00	7.00	8.00	8.00	5.00	5.00	4.00	3.00
Shareholder's Equity	72.7%	354	205	143	148	162	180	195	211	226	243	256	267	-	-
Retained Earnings	-21.5%	-75.36	-62.05	-208	-201	-187	-19.93	-146	-127	-109	-90.85	-76.61	-63.70	-52.30	-43.01
Additional Paid-In Capital	60.9%	430	267	352	351	349	0.00	342	339	336	334	332	331	6.00	5.00
Shares Outstanding	26.1%	26.00	20.00	4.00	43.00	42.00	-	4.00	41.00	41.00	40.00	25.00	17.00	-	-
Float	-	-	-	-	90.00	-	-	-	139	-	-	-	280	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-235.4%	-14,923	11,021	-7,502	-14,698	-16,902	40,529	-13,427	-17,280	-16,280	-9,842	-10,129	-10,982	-9,047	-5,650	-4,826	-3,493	-5,243
Share Based Compensation	544.9%	1,388	-312	1,248	1,174	3,659	-7,889	3,041	2,846	2,197	994	1,053	896	835	593	186	120	123
Cashflow From Investing	-113.6%	-188,869	-88,418	55,929	8,919	27,410	-51,727	6,304	19,928	20,427	721	1,694	-100,132	1,330	-104,363	-13,048	3,566	-19,455
Cashflow From Financing	3.1%	161,352	156,463	74.00	137	46.00	19,668	73.00	79.00	30.00	412	-551	137,522	17.00	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TALS Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 11,376	$ 6,137
General and administrative	6,141	1,365
Total operating expenses	17,517	7,502
Loss from operations	(17,517)	(7,502)
Other income, net	4,206	0
Net loss	$ (13,311)	$ (7,502)
Net loss per share, basic (usd per share)	$ (0.55)	$ (8.28)
Net loss per share, diluted (usd per share)	$ (0.55)	$ (8.28)
Weighted-average, common shares outstanding, basic (in shares)	24,082	906
Weighted-average, common shares outstanding, diluted (in shares)	24,082	906
Other comprehensive loss:
Unrealized loss on investments	$ (320)	$ 0
Comprehensive loss	$ (13,631)	$ (7,502)

TALS Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 98,286	$ 140,726
Short-term investments	194,773	62,225
Prepaid expenses and other current assets	7,040	5,923
Total current assets	300,099	208,874
Property and equipment, net	75	85
Total long-term investments	57,237	0
Restricted cash	227	227
Operating lease right-of-use asset	327	362
Other non-current assets	1,204	747
Total assets	359,169	210,295
Current liabilities
Accounts payable	1,936	1,071
Accrued expenses and other current liabilities	2,668	3,710
Operating lease liability, current portion	223	221
Total current liabilities	4,827	5,002
Operating lease liability, net of current portion	153	194
Other liabilities	50	57
Total liabilities	5,030	5,253
Commitments and Contingencies (Note 11)
Stockholders’ equity
Undesignated preferred stock, $0.0001 par value – 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023, no shares issued or outstanding as of March 31, 2024 or December 31, 2023	0	0
Common stock, $0.0001 par value – 140,000,000 voting shares authorized as of March 31, 2024 and December 31, 2023, 25,646,509 and $20,337,571 voting shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively; 10,000,000 non-voting shares authorized as of March 31, 2024 and December 31, 2023, no non-voting shares issued or outstanding as of March 31, 2024 or December 31, 2023	3	2
Additional paid-in capital	429,751	267,024
Accumulated other comprehensive (loss) income	(253)	67
Accumulated deficit	(75,362)	(62,051)
Total stockholders’ equity	354,139	205,042
Total liabilities and stockholders’ equity	$ 359,169	$ 210,295

About Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

CEO	Ms. Mary Kay Fenton
WEBSITE	https://talaristx.com
INDUSTRY	Biotechnology
EMPLOYEES	84

Talaris Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Talaris Therapeutics, Inc.? What does TALS stand for in stocks?

TALS is the stock ticker symbol of Talaris Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Talaris Therapeutics, Inc. (TALS)?

As of Tue Apr 30 2024, market cap of Talaris Therapeutics, Inc. is 73.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TALS stock?

You can check TALS's fair value in chart for subscribers.

What is the fair value of TALS stock?

You can check TALS's fair value in chart for subscribers. The fair value of Talaris Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Talaris Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TALS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Talaris Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TALS is over valued or under valued. Whether Talaris Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Talaris Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TALS.